Data sets up 2021 filings for Gilead’s twice-a-year HIV drug lenacapavirGilead Sciences has the data it was hoping for in a pivotal trial of lenacapavir, an HIV drug Share XData sets up 2021 filings for Gilead’s twice-a-year HIV drug lenacapavirhttps://pharmaphorum.com/news/data-sets-up-2021-filings-for-gileads-twice-a-year-hiv-drug-lenacapavir/
ViiV could challenge Gilead with long-acting HIV PrEP shotGlaxoSmithKline’s HIV joint venture ViiV Healthcare could mount a challenge to Gilead’s HIV pre-exposure prophylaxis (PrEP) medicines after Share XViiV could challenge Gilead with long-acting HIV PrEP shothttps://pharmaphorum.com/news/viiv-could-challenge-gilead-with-long-acting-hiv-prep-shot/
Finding resilience after an HIV diagnosisAuthor and journalist John-Manuel Andriote has spent much of his career writing about the impact of HIV/AIDS – Share XFinding resilience after an HIV diagnosishttps://pharmaphorum.com/views-analysis-patients/finding-resilience-hiv-diagnosis/
ViiV gets FDA nod for Rukobia drug for older HIV patientsThe FDA has approved Rukobia, a first-in-class drug from ViiV Healthcare intended for older people with HIV, who Share XViiV gets FDA nod for Rukobia drug for older HIV patientshttps://pharmaphorum.com/news/viiv-gets-fda-nod-for-rukobia-drug-for-older-hiv-patients/
China’s coronavirus vaccine could be ready for trials next monthChinese officials say that a coronavirus vaccine could be ready for clinical trials and emergency situations next month Share XChina’s coronavirus vaccine could be ready for trials next monthhttps://pharmaphorum.com/news/chinese-coronavirus-vaccine-could-be-ready-for-trials-next-month/
Stem cell transplant eradicates HIV in second patientA second man with HIV has been cured of the infection after receiving a transplant of stem cells Share XStem cell transplant eradicates HIV in second patienthttps://pharmaphorum.com/news/stem-cell-transplant-eradicates-hiv-in-second-patient/
ViiV’s two-drug HIV therapy Dovato gets Japanese approvalOne of ViiV Healthcare’s two-drug HIV therapies – Dovato – has been approved in Japan, providing a new Share XViiV’s two-drug HIV therapy Dovato gets Japanese approvalhttps://pharmaphorum.com/news/viivs-two-drug-hiv-therapy-dovato-gets-japanese-approval/
ViiV files first-in-class HIV drug in EuropeViiV Healthcare has filed its new HIV drug fostemsavir for approval in Europe, a few weeks after the Share XViiV files first-in-class HIV drug in Europehttps://pharmaphorum.com/news/viiv-files-first-in-class-hiv-drug-in-europe/
FDA knocks back ViiV, J&J’s long-acting HIV regimenPeople with HIV hoping to be freed from daily doses of tablets will have to wait a little Share XFDA knocks back ViiV, J&J’s long-acting HIV regimenhttps://pharmaphorum.com/news/fda-knocks-back-viiv-jjs-long-acting-hiv-regimen/
